Idenix Pharmaceuticals (IDIX)

[Mufaso]

Intermunes spike Monday of $5.05, to $18.43 added roughly $200 million to ITMN’s market cap. This an example of what mildly positive news on a HCV drug trial can do to a stock.

If Idenix is able to achieve it’s goal of an IND and phase I trial completion for IDX 184, in 2008, I would expect that to add at least $200 million to it’s cap.

Cash in the bank, a strong partner and an approved drug in Tyzeka limit the downside. Given the pipeline includes another HCV drug (IDX 102) and a HIV drug in IDX899, I like the risk reward proposition that Idenix offers.